Sinopharm Group Co Liabilities 2025

Sinopharm Group Co Aktienanalyse

What does Sinopharm Group Co do?

Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Sinopharm Group Co's Liabilities

Sinopharm Group Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sinopharm Group Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Sinopharm Group Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Sinopharm Group Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Sinopharm Group Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Sinopharm Group Co stock

What is the level of liabilities of Sinopharm Group Co this year?

Sinopharm Group Co has a debt balance of 313.95 B CNY this year.

What were the liabilities of Sinopharm Group Co compared to the previous year?

The liabilities of Sinopharm Group Co have increased by 1.66% increased compared to the previous year.

What are the consequences of high debt for investors of Sinopharm Group Co?

High liabilities can pose a risk for investors of Sinopharm Group Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Sinopharm Group Co?

Low liabilities mean that Sinopharm Group Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Sinopharm Group Co affect the company?

An increase in liabilities of Sinopharm Group Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Sinopharm Group Co affect the company?

A decrease in the liabilities of Sinopharm Group Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Sinopharm Group Co?

Some factors that can influence the liabilities of Sinopharm Group Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Sinopharm Group Co so important for investors?

The liabilities of Sinopharm Group Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Sinopharm Group Co take to modify the liabilities?

To change its liabilities, Sinopharm Group Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Sinopharm Group Co pay?

Over the past 12 months, Sinopharm Group Co paid a dividend of 0.96 CNY . This corresponds to a dividend yield of about 5.57 %. For the coming 12 months, Sinopharm Group Co is expected to pay a dividend of 1.04 CNY.

What is the dividend yield of Sinopharm Group Co?

The current dividend yield of Sinopharm Group Co is 5.57 %.

When does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Sinopharm Group Co?

Sinopharm Group Co paid dividends every year for the past 20 years.

What is the dividend of Sinopharm Group Co?

For the upcoming 12 months, dividends amounting to 1.04 CNY are expected. This corresponds to a dividend yield of 6.04 %.

In which sector is Sinopharm Group Co located?

Sinopharm Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinopharm Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinopharm Group Co from 8/12/2025 amounting to 0.739 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2025.

When did Sinopharm Group Co pay the last dividend?

The last dividend was paid out on 8/12/2025.

What was the dividend of Sinopharm Group Co in the year 2024?

In the year 2024, Sinopharm Group Co distributed 0.9 CNY as dividends.

In which currency does Sinopharm Group Co pay out the dividend?

The dividends of Sinopharm Group Co are distributed in CNY.